-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the performance forecasts of listed pharmaceutical companies in the interim report have been disclosed one after another, and the companies that have disclosed their performance have performed we.
Among them, in the field of in vitro diagnostics (IVD), with the continuous increase in industry concentration, leading companies have achieved remarkable resul.
The growth rate of Angene's two companies is more than 10
Dean Diagnostics: Net profit attributable to the parent increased by 1206%-1632% Y.
Its growth rate has outpaced the company's annual net profit growth over the past five yea.
Regarding the reasons for the growth in performance, the company stated that during the reporting period, the company anchored the positioning of "provider of integrated medical diagnosis solutions", and promoted the implementation from strategy to execution in an orderly manner as plann.
At the same time, in the first half of the year, the company's traditional diagnostic service business maintained rapid growth, its self-produced product business grew rapidly, and its channel product business grew steadi.
According to the data, Dean Diagnostics is a leading company in the domestic third-party medical diagnosis industry, and has now become an "integrated solution provider for medical diagnosi.
Development is its own characteristic, and it will make every effort to open up new formats of the whole industry cha.
Regarding the performance of Dean's diagnosis in the later stage, Zhongtai Securities believes that the company's long-term positive trend remains unchanged, and the head ICL is expected to continue to grow rapid.
Another brokerage believes that the third-party medical testing service conforms to the national policy orientation and the future trend of the industry, and is expected to help the hospital laboratory department to reduce costs and control expenses, achieve an increase in the outsourcing rate, and the scale effect and comprehensive service capability advantages of the head ICL will become more and more promine.
An Diagnostics is expected to maintain rapid growth in the medium to long te.
Daan Gene: Net profit increased by 1259% year-on-year Daan Gene released the 2022 semi-annual performance report on July 28, showing that the revenue in the first half of the year was 676 billion yuan, a year-on-year increase of 968%; operating profit was 313 billion yuan, a year-on-year increase of 1312% ; The net profit attributable to shareholders of listed companies was 557 billion yuan, a year-on-year increase of 1259%
Regarding the reasons for the growth in performance, the company stated that during the reporting period, the company provided nucleic acid detection products as one of the core suppliers of domestic new crown nucleic acid diagnosis products; market demand for 2019-nCoV nucleic acid detection kits, nucleic acid detection instruments, and related consumables continu.
had a positive impact on the company's performan.
According to the data, Daan Gene is a biological product company engaged in the production and sales of fluorescent PCR detection kits and medical equipment, as well as the provision of clinical inspection servic.
It is worth mentioning that on July 18, Daan Gene also accepted the investigation of a group of institutio.
Regarding the question of future layout, Daan Gene replied that the company will fully enter the whole field of IVD in the future, focusing on diagnos.
The application of technologies and products in clinical, public health, inspection and quarantine, and life and health-related fields will continue to expand and strengthen PCR and molecular diagnostic technologies, products and market fields, and actively develop comprehensive diagnostic technology platforms such as immunity, biochemistry, and analytical instrumen.
, product and market secto.
Secondly, the company will continue to adhere to the technology, product, market and industrial development that combines independent research and development, independent innovation with imported development and industrial investme.
Conclusion In recent years, the in vitro diagnostic industry has developed rapid.
Data show that from 2015 to 2018, the domestic market size of the in vitro diagnostic industry has increased from 32 billion yuan to 64 billion yuan, and the growth rates from 2016 to 2018 were 178% and 160%, respective.
% and 14
In the context of the rapid development of the industry, the number of players who have deployed this track has gradually increas.
The industry believes that in the future, leading companies with innovative R&D capabilities, product pipelines and iteration capabilities will embrace more opportuniti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Among them, in the field of in vitro diagnostics (IVD), with the continuous increase in industry concentration, leading companies have achieved remarkable resul.
The growth rate of Angene's two companies is more than 10
Dean Diagnostics: Net profit attributable to the parent increased by 1206%-1632% Y.
Its growth rate has outpaced the company's annual net profit growth over the past five yea.
Regarding the reasons for the growth in performance, the company stated that during the reporting period, the company anchored the positioning of "provider of integrated medical diagnosis solutions", and promoted the implementation from strategy to execution in an orderly manner as plann.
At the same time, in the first half of the year, the company's traditional diagnostic service business maintained rapid growth, its self-produced product business grew rapidly, and its channel product business grew steadi.
According to the data, Dean Diagnostics is a leading company in the domestic third-party medical diagnosis industry, and has now become an "integrated solution provider for medical diagnosi.
Development is its own characteristic, and it will make every effort to open up new formats of the whole industry cha.
Regarding the performance of Dean's diagnosis in the later stage, Zhongtai Securities believes that the company's long-term positive trend remains unchanged, and the head ICL is expected to continue to grow rapid.
Another brokerage believes that the third-party medical testing service conforms to the national policy orientation and the future trend of the industry, and is expected to help the hospital laboratory department to reduce costs and control expenses, achieve an increase in the outsourcing rate, and the scale effect and comprehensive service capability advantages of the head ICL will become more and more promine.
An Diagnostics is expected to maintain rapid growth in the medium to long te.
Daan Gene: Net profit increased by 1259% year-on-year Daan Gene released the 2022 semi-annual performance report on July 28, showing that the revenue in the first half of the year was 676 billion yuan, a year-on-year increase of 968%; operating profit was 313 billion yuan, a year-on-year increase of 1312% ; The net profit attributable to shareholders of listed companies was 557 billion yuan, a year-on-year increase of 1259%
Regarding the reasons for the growth in performance, the company stated that during the reporting period, the company provided nucleic acid detection products as one of the core suppliers of domestic new crown nucleic acid diagnosis products; market demand for 2019-nCoV nucleic acid detection kits, nucleic acid detection instruments, and related consumables continu.
had a positive impact on the company's performan.
According to the data, Daan Gene is a biological product company engaged in the production and sales of fluorescent PCR detection kits and medical equipment, as well as the provision of clinical inspection servic.
It is worth mentioning that on July 18, Daan Gene also accepted the investigation of a group of institutio.
Regarding the question of future layout, Daan Gene replied that the company will fully enter the whole field of IVD in the future, focusing on diagnos.
The application of technologies and products in clinical, public health, inspection and quarantine, and life and health-related fields will continue to expand and strengthen PCR and molecular diagnostic technologies, products and market fields, and actively develop comprehensive diagnostic technology platforms such as immunity, biochemistry, and analytical instrumen.
, product and market secto.
Secondly, the company will continue to adhere to the technology, product, market and industrial development that combines independent research and development, independent innovation with imported development and industrial investme.
Conclusion In recent years, the in vitro diagnostic industry has developed rapid.
Data show that from 2015 to 2018, the domestic market size of the in vitro diagnostic industry has increased from 32 billion yuan to 64 billion yuan, and the growth rates from 2016 to 2018 were 178% and 160%, respective.
% and 14
In the context of the rapid development of the industry, the number of players who have deployed this track has gradually increas.
The industry believes that in the future, leading companies with innovative R&D capabilities, product pipelines and iteration capabilities will embrace more opportuniti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
